Prothena soars on Phase I Parkinson's data

Prothena Corp. plc (NASDAQ:PRTA) rose $9.43 (32%) to $38.66 on Friday after it said Parkinson's disease (PD) candidate PRX002 reduced free serum alpha synuclein ( SNCA) levels by up to 96% in a Phase I trial (p<0.00001). The single ascending dose study included 40 healthy volunteers who received 0.3, 1, 3, 10 or 30 mg/kg of PRX002 or placebo. Prothena expects data from an ongoing multiple ascending dose trial in PD patients in 1H16.

Prothena and Roche (SIX:ROG; OTCQX:RHHBY) partnered in 2013 to co-develop and co-commercialize the mAb targeting SNCA (see BioCentury Extra, Dec. 11, 2013). ...